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The Impact of  Quarantines, Lockdowns, and 
‘Reopenings’ on the Commercialization of  Science: 
Micro and Macro Issues
Donald S. Siegela  and Maribel Guerrerob,c,d
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ABSTRACT In 2020, almost all research labs in industry, academia, and the government were 
shut down for long periods of  time by political leaders to control the spread of  the coronavirus. 
We consider the “micro” and “macro” implications of  ongoing coronavirus disruptions in scien-
tific research and the dissemination and commercialization of  that research. We have identified 
three key unanswered research questions regarding these unprecedented disruptions: (1) How is 
the pandemic affecting conventional measures of  scientific output (the quantity and quality of  
basic research) and performance, social networks, and the strategic management of  innovation? 
(2) How is the pandemic affecting technology transfer offices, incubators, accelerators, science 
and technology parks, and other aspects of  the innovation ecosystem? (3) How do pandemic 
disruptions affect micro- level factors, such as role conflict, identity, work- life balance, equity, 
diversity, inclusion, “championing,” leadership, and organizational justice?
Keywords: championing/leadership, commercialization of  science, COVID- 19 pandemic, 
public- private partnerships, scientific workplace, social networks, work- life balance
INTRODUCTION
2020 was the 40th anniversary of  two landmark pieces of  legislation in the USA: the 
Bayh- Dole and Stevenson- Wydler Acts. These acts incentivized the commercialization 
of  science at universities and federal/national labs, where most basic research is con-
ducted. Such legislation and the concomitant rise of  technology transfer at universities 
and federal/national labs inspired other nations to adopt similar laws (Guerrero and 
Urbano, 2019), resulting in a substantial increase in patenting, licensing, start- ups, and 
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collaborations with industry and entrepreneurs. Unfortunately, 2020 was also a year 
when almost all research labs in industry, academia, and government were shut down for 
long periods of  time by political leaders to control the spread of  the coronavirus.
Previous JMS’ COVID- 19 commentaries have focused mainly on the antecedents and 
consequences of  firm responses to the pandemic. In contrast, we consider both ‘micro’ 
and ‘macro’ implications of  ongoing coronavirus workplace disruptions, that is, quaran-
tines, lockdowns, and re- openings, on the scientific workplace at universities and federal/
national labs. Such disruptions constitute fertile ground for theoretical and empirical 
research on the commercialization of  science. We have identified some promising new 
avenues of  research on this topic.
Re- Configuration of  Production, Dissemination, and Commercialization 
of  Science
According to Markman et al. (2008), the traditional scientific process combines knowl-
edge modes and methods involving three dimensions: (1) The individual dimension re-
lated to the heterogeneity of  entrepreneurial teams, experiences, and related incentives; 
(2) The organizational dimension related to corporate governance, relationships with 
trading partners or intermediaries, and boundary- spanning activities; (3) The institu-
tional dimension related to technological valuation and personal injury protection (PIP). 
The COVID- 19 pandemic has re- configured this ‘traditional’ process as follows:
First, scientific producers have re- oriented their priorities due to the pandemic, to focus 
on imminent threats to humanity. The pandemic has also led to re- configuration of  
the ‘supply’ of  basic research (digital scientific workplaces), new knowledge production 
modes (co- production modes and new rules of  the game related to intellectual property 
protection), demand for efficient scientific funding process (efficiency in review processes 
and allocation of  funds), and an expansion of  geographic scope (initially centred on the 
flow of  information related to COVID- 19 from Chinese institutions and the emergence 
of  global networks for responding to the pandemic).
An inability to conduct basic research may have enabled scientists to devote more 
attention to patenting, licensing, and start- up formation relating to new or existing tech-
nologies, especially in the life sciences, where it is much more difficult to conduct non- 
related COVID- 19 basic research remotely. For example, Kubota (2021) reports that 
some Stanford researchers who do not conduct COVID- 19 basic research are devoting 
more time to publications and technology transfer.
Second, the scientific discovery/dissemination cycle for scientists not engaged in coronavirus- 
related basic and applied research has been interrupted or substantially curtailed during 
the COVID- 19 pandemic. Quarantines and lockdowns have shut down conferences, 
seminars, and other social events where knowledge is disseminated, collaboration occurs, 
funding sources are identified, and discoveries emerge. Also, many clinical trials and early 
stage research projects that could lead to life- saving treatments worldwide have been aban-
doned due to lockdowns or because funding has been discontinued (AMRC, 2020). NPR 
reported that clinical trials for many important cancer drugs were interrupted (Lupkin, 
2020). In the USA, non- COVID- 19 research operations at universities, medical schools, 
and federal labs (most located in states with severe lockdowns) have also been shut down, 
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leading to the cancellation of  basic and applied research on cancer, heart disease, hyper-
tension, Alzheimer’s disease, and other diseases that kill millions each year (WHO, 2020).
In contrast, we have also observed faster dissemination of  scientific publications re-
garding discoveries related to coronavirus (treatments, vaccines, and studies of  broader 
impacts) through virtual workshops and academic journals (where the editorial process 
usually takes more than 1– 2 years). The thoughtful academic and policymakers’ de-
bate focused on intellectual protection and commercialization mechanisms of  current 
discoveries.
Third, scientific commercialization related to the coronavirus has flourished by transferring the 
discoveries to final users according to the national health organizations’ controls. In this 
phase, the main challenge has been full disclosure of  all information related to corona-
virus research and access to medicines that treat the virus. Pharmaceutical patents have 
restricted access to generic supplier companies. Consequently, the US federal government 
has attempted to secure exclusive rights to any vaccine created, while the German federal 
government has offered to pharmaceuticals to buy the rights to the vaccine. Other adminis-
trations have also revived the figure of  compulsory licensing to facilitate access to vaccines, 
drugs, or technological devices. Nationalistic commercialization practices have promoted 
not only international cooperation but also international competition (WEF, 2021).
In contrast, we observe that although patent and trademark associations had modified 
their operational forms by introducing deadline extensions and fee waivers (see Amin- 
Reimer and Christensen, 2020), scientific commercialization unrelated to the coronavirus appears to 
have languished (technology transfer offices are reporting that patent applications are down).
Effects on Social Networks and Public- Private Partnerships
Social networks involving ‘star’ scientists and their ‘offspring’ and collaborators have 
been shown to be important in the commercialization of  science, in terms of  stimulating 
patenting and start- up creation. Networks of  academic scientists who become entre-
preneurs may also be important influences on the performance of  such start- ups. For 
instance, depending on their cooperation arrangements with other public and/or private 
bodies, the academic social network has been shown to have a favourably impact on the 
growth trajectory of  start- ups and their rate of  survival. Differences in the embeddedness 
of  academics in a network of  ties external or internal to the university may be associated 
with different growth trajectories.
COVID- 19 has stimulated N- Helix collaborations1 among the public sector, supply 
chain industrial actors, non- profit organizations, and civil citizens. As a result, we have 
observed multiple collaborative initiatives in different stages (in preparation, pilots, demos, 
trials or ready) associated with the prevention (sanitation, automatization, vaccination), the 
diagnosis (telehealth diagnosis, bigdata, test kits), the treatment (medication, ventilators, 
medical devices), the information (databases, communications), and the life adaptation (ed-
ucation, work, shopping, metal health). Indeed, several grants or supporting initiatives have 
emerged for connecting entrepreneurs, innovators, investors, social media, and society. 
Contrarily, non- related coronavirus researchers have temporarily paused existing or new 
collaboration agreements due to the government lockdown and quarantine uncertainty.
The best example of  partnership disruption in the COVID- 19 era has been the land-
mark agreement between AstraZeneca and the University of  Oxford for the coronavirus 
4 D. S. Siegel and M. Guerrero 
© 2021 The Authors. Journal of  Management Studies published by Society for the Advancement of  Management Studies 
and John Wiley & Sons Ltd.
vaccine (known as ChAdOx1 nCoV- 19). This public- private partnership enables world-
wide development, manufacturing, and distribution of  this vaccine, especially in low 
and middle- income countries. It has been guaranteed by a longstanding relationship of  
trust and success to advance basic research between these scientific places (AstraZeneca, 
2020). It explains the rapid configuration of  this disruptive collaboration integrated by 
an extraordinarily talented team of  scientists (representing the best tradition of  research, 
teaching, and commercialization driving the university’s mission for centuries) and a new 
partner (Vaccitech).
Effects on the Measurement of  Research and Commercialization 
Performance
Scientific productivity is usually measured using three proxies: number of  patents 
granted, number of  products in development, and number of  products on the mar-
ket. Public- private collaborations that enrolled ‘star’ scientists and ‘industrial’ scientists 
positively affect scientific productivity metrics. COVID- 19 will produce a disruption on 
the productivity metrics of  scientific places that were ‘winners’ and ‘losers’. ‘Winners’ 
will show good indicators in terms of  patents, innovations, markets as well as knowledge 
spill- overs effects, and socio- economic externalities. Contrarily, ‘losers’ will show a drop 
in productivity indicators. Future official statistics will undoubtedly offer insights about 
the resilience or decline effects of  COVID- 19 on these scientific places across the globe.
Effects of  Coronavirus Restrictions on the Scientific Workplace- Micro 
Issues
The pandemic is also affecting micro- level factors that may be critical in the commercial-
ization of  research, such as role conflict, identity, work- life balance, ‘championing’, and 
leadership (Balven et al., 2018). In this context, identity refers to the fact that when we 
encourage scientists to engage in the commercialization of  their research, we are asking 
them to assume a new identity as an entrepreneur or, in some cases, to become public 
figures/celebrities (e.g., Neil Ferguson in the UK). This may lead to conflict with their 
traditional roles and identities as scientists and teachers.
Involvement in technology transfer also presents challenges, in terms of  work- life bal-
ance. In normal times, scientists may be interested in pursuing commercialization, but 
feel too time- constrained to do so. Given that many children have (physically) out of  
school for 10 months, parents have had to devote more time to caring for their children 
at home. Another important individual- level phenomenon is the role of  leadership on 
the part of  department chairs and senior faculty at universities and senior scientists at 
federal labs, which can involve inspiring junior scientists to engage in technology transfer. 
Leaders and managers can also ‘champion’ these activities through their own endeav-
ours, and thus, serve as a role model for scientists who wish to engage in these activities. 
Alternatively, they may simply provide support (time allocation) for subordinates to pur-
sue commercialization of  their research. It is important for micro researchers to study 
how the pandemic is affecting the scientific workplace and the propensity of  scientists 
to commercialize their research. We also need to learn more about how these ongoing 
scientific workplace disruptions are affecting research and commercialization.
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Promising New Avenues of  Research
In sum, we have identified three new areas of  micro and macro research on how the 
pandemic is affecting the commercialization of  science:
1. How is the pandemic affecting conventional measures of  scientific output (the quantity 
and quality of  basic research) and performance, social networks, and the strategic man-
agement of  innovation, including the commercialization of  research? This includes 
an analysis of  its effects on collaborative research and commercialization, including 
public- private partnerships and other university- industry collaborations.
2. How is the pandemic affecting innovation intermediaries and the entrepreneurial 
ecosystem, including technology transfer offices, incubators, accelerators, science and 
technology parks, and other aspects on the innovation ecosystem? This has important 
public policy implications, given that there is substantial public investment in property- 
based institutions and high technology economic development initiatives.
3. We also need a better understanding of  how the pandemic is affecting the scien-
tific workforce, especially those who may potentially be involved in commercializa-
tion efforts. This means that management scholars should explore the importance of  
micro- level factors, such as role conflict, identity, work- life balance, ‘championing’, or-
ganizational justice, and leadership. Such research will help us determine how to better 
manage the scientific workforce and the process of  research commercialization under 
trying conditions.
NOTE
[1] The triple helix model of  innovation refers to a set of  interactions between academia, government, and 
other organizational actors.
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